how to keep weight off after stopping glp 1 medication Maintain Loss GLP-1 – KETO-MOJO What happens when you stop

Jacqueline Maya , a pediatric endocrinologist and physician-investigator at Massachusetts General Hospital who studies how events in pregnancy impact the health of both mother and child

By breaking food down more thoroughly before swallowing, you make the stomachs job easier

Improved metabolic flexibility Obesity and type 2 diabetes are commonly associated with impaired metabolic flexibility, meaning the body has difficulty switching efficiently between glucose and fat oxidation

it addresses both the cellular trigger (oxidative stress in the mast cell) and the systemic clearance mechanism (hepatic detoxification)

CagriSema vs Comparators Feature Receptor targets CagriSema Amylin/calcitonin + GLP-1 Tirzepatide (Zepbound) GIP + GLP-1 Semaglutide alone (Wegovy) GLP-1 Cagrilintide alone Amylin/calcitonin (DACRA) Feature Dosing frequency CagriSema Once weekly Tirzepatide (Zepbound) Once weekly Semaglutide alone (Wegovy) Once weekly Cagrilintide alone Once weekly Feature Maintenance dose CagriSema 2.4 mg + 2.4 mg Tirzepatide (Zepbound) Up to 15 mg Semaglutide alone (Wegovy) 2.4 mg Cagrilintide alone 2.4 mg (in REDEFINE arms) Feature Headline weight loss CagriSema 20.4% at 68 wks (REDEFINE 1, treatment-policy) Tirzepatide (Zepbound) Up to 22.5% at 72 wks (SURMOUNT-1, 15 mg arm) Semaglutide alone (Wegovy) 14.9% at 68 wks (REDEFINE 1 reference arm) Cagrilintide alone 11.5% at 68 wks (REDEFINE 1 reference arm) Feature FDA status (June 2026) CagriSema NDA filed Dec 2025

While GLP-1 receptor agonists like tirzepatide and semaglutide have revolutionized obesity treatment, emerging evidence suggests that strategic compounding with complementary agents may enhance therapeutic outcomes